Funding for this research was provided by:
National Natural Science Foundation of China (81630001)
National Innovative Research Team of High-level Local Universities in Shanghai (2018YFE0102400)
Shanghai Shenkang Hospital Development Center Clinical Science and Technology Innovation Project (SHDC12018102, SHDC2020CR1002A)
Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai (20dz2261100)
Received: 29 March 2022
Accepted: 13 May 2022
First Online: 26 May 2022
: The MEXCOVID study was approved by the Ethics Commission of Jinyintan hospital, Wuhan, China as well as Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China (KY2020-32). Written Informed consent was obtained after discussion with patient or an appropriate surrogate.
: Consent for publication involving individual details, images and lab results have been obtained from all the patients.
: The authors declare that they have no competing interests.